Michele Solis is a freelance science writer based in Seattle, Washington
First described 200 years ago, Parkinson’s disease remains without a cure. After many failed clinical trials, researchers are getting back to basics to try to gain a better understanding of the challenges, and a new generation of treatment ideas are now in clinical trials, some of which aim to stall progression of the disease.
Parents of children with treatment-resistant epilepsy are searching for something to help, and some are turning to cannabis to try to reduce seizure frequency. With clinical trials of cannabidiol-based drugs under way, evidence for this treatment option may soon be forthcoming. However, concerns remain about side effects, such as sedation, interactions with other drugs, and potential disturbances of brain development.
As more people are being diagnosed with coeliac disease, the first drug treatments are entering clinical trials, but success is proving difficult to measure.
Autism: in search of new drug targetsSubscription
Heroin abuse: breaking the cycleSubscription